Previous Study: TRIO014
Next Study: TRIO016
Studies & Results
TRIO015
A multicenter open label Phase II study of the efficacy and safety of AMG 479, a fully human monoclonal antibody against insulin-like growth factor Type 1 receptor (IGF-1R) as second line therapy in patients with recurrent platinum-sensitive ovarian cancer
View FDA Study View EU Study
Presentations
ASCO Annual Meeting, 2013
Ray-Coquard I, Haluska P, O’Reilly S, et al
A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer.
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org
Presentations
ASCO Annual Meeting, 2013
Ray-Coquard I, Haluska P, O’Reilly S, et al
A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer.
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org